GLP-1 cost, insurance, and Medicare in 2026.

"What does this drug actually cost?" is the most common question people ask after a first prior-authorization denial, and the honest answer depends on more variables than most prescriptions: indication on the label, which PBM runs your plan, Medicare versus commercial coverage, and whether a manufacturer savings card applies. The list price is a starting point, not a forecast.

This article makes that "it depends" concrete as of May 2026: what each branded GLP-1 lists for, what commercial insurance typically does with it, what changes for Medicare on July 1, what manufacturers offer directly, where Medicaid stands, and what happened to the compounded pathway. Pricing in this space moves; we date-stamp the snapshot. This is not financial advice and it is not a recommendation to choose one medication over another: the comparison between Ozempic, Wegovy, Mounjaro, and Zepbound is a clinical decision that belongs with your prescriber. We document the closure of the compounded semaglutide pathway without recommending it; that legal cover has been dismantled.

Cost landscape at a glance.

All figures are US list prices per 28-day supply as of May 2026. Real out-of-pocket cost varies sharply by insurance, pharmacy, dose, and savings program eligibility. The sources block links to the official pages where current numbers live.

Compounded semaglutide and tirzepatide were available from large compounding operations in the $200 to $400 range during the 2023 to 2024 shortage window. That window closed in stages between February and May 2025, and in April 2026 the FDA proposed permanent exclusion from the 503B Bulks List. Details below.

The Medicare GLP-1 Bridge.

The largest change to the GLP-1 cost landscape since these drugs reached market is a CMS demonstration called the Medicare GLP-1 Bridge, launching July 1, 2026. Medicare has historically excluded coverage of any drug used "for anorexia, weight loss, or weight gain" under statute, which is why obesity indications of GLP-1 medications have not been covered by standard Part D. The Bridge is a temporary workaround under Section 402 demonstration authority while the longer-term BALANCE Model is built.

The Medicare GLP-1 Bridge is the biggest single shift in the obesity-medication cost landscape since these drugs reached market. It is also temporary.

Who qualifies.

A beneficiary must be enrolled in standalone Part D or a Medicare Advantage plan with drug coverage, be 18 or older, and meet one of three BMI and clinical criteria tiers:

• BMI of 35 or higher, with no additional condition required, or
• BMI of 30 or higher with a diagnosis of heart failure, uncontrolled hypertension, or chronic kidney disease, or
• BMI of 27 or higher with a diagnosis of pre-diabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.

What it costs.

A flat $50/month copay at the pharmacy counter, with a central processor handling payment behind the scenes. That is a transformation for beneficiaries previously looking at $1,300/month at list. It is also still $600 a year, with fine print:

• The $50 copay does not count toward the Part D out-of-pocket cap of $2,100 in 2026.
• Bridge drug spending does not count toward Part D covered drug costs.
• Low-Income Subsidy (LIS) recipients cannot apply LIS to Bridge prescriptions, so the $50 may be a real barrier for the group Medicare normally protects most aggressively.
• Beneficiaries already on a GLP-1 for type 2 diabetes, sleep apnea, or another covered Medicare indication stay on normal plan cost-sharing, even if higher than $50.

Which drugs are in.

All formulations of Wegovy (semaglutide), the new oral semaglutide product Foundayo, and the KwikPen multi-dose formulation of Zepbound (tirzepatide). The single-dose Zepbound pen is not in the Bridge; a prescriber writing Zepbound for a Medicare beneficiary needs to specify KwikPen for the Bridge benefit to apply.

What comes after.

The longer-term path is the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a five-year CMS Innovation Center demonstration introduced December 2025 to negotiate lower GLP-1 prices. To continue Medicare coverage of GLP-1s for obesity past December 31, 2027, a beneficiary would need a Part D plan that elected to participate in BALANCE. KFF flags the Bridge alone is likely to add "billions of dollars a year" to Medicare spending, which is why the long-term solution depends on price negotiation.

Whether you qualify for the Bridge depends on diagnoses on your medical record. Confirm with your Medicare plan and your prescriber before assuming eligibility.

Commercial insurance and PBM dynamics.

"Covered" is a slippery word in the GLP-1 space. Three layers shape what a commercially-insured person actually pays.

Indication-driven coverage.

Type 2 diabetes is widely covered. Obesity is not. The same active molecule (semaglutide) is generally easier to get covered under its diabetes label (Ozempic, Rybelsus) than its obesity label (Wegovy). The molecule is the same; the policy keys to the FDA-approved indication on the label, which the prescription must match. Which indication applies to you is a clinical conversation with your prescriber, not a cost-saving lever to pull.

Same molecule, different label, different coverage. That is the PBM logic at work, and it is why two people on the same plan can have wildly different out-of-pocket experiences.

PBM formulary tiers.

Pharmacy benefit managers place each drug on a tier: preferred, non-preferred, specialty, or excluded. Tier placement drives the copay or coinsurance. PBMs negotiate rebates with manufacturers for preferred placement, and a drug that loses its rebate fight can disappear from a formulary at the next plan year. KFF's 2025 employer survey found roughly 42% of large employers (1,000+ employees) cover at least one GLP-1 for obesity, while only about 18% of small employers (under 200) do.

Prior authorization and step therapy.

Common requirements for GLP-1 obesity coverage:

• Documented BMI threshold (typically 30+, or 27+ with one comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea).
• Documentation of prior lifestyle intervention, often 3 to 6 months of diet and exercise records.
• For step therapy plans: prior trial and failure of a lower-cost agent such as phentermine, Contrave, or in some plans liraglutide.

Two people on the same employer's plan can have very different out-of-pocket realities depending on dose, pharmacy, and which prior-authorization criteria the plan currently enforces. Your specific plan's criteria are the only ones that matter for your prescription. Call member services.

Manufacturer savings programs.

Both major manufacturers run savings programs that lower the cost for some patients. Eligibility is restricted in ways the article-level summary often skips; current rules are below, with links to the manufacturer pages for the version that is live the day you read this.

Eli Lilly: Mounjaro and Zepbound savings card.

• Eligible commercially-insured patients with coverage for the drug may pay as little as $25 for a one-, two-, or three-month fill.
• Maximum savings up to $100 (one-month), $200 (two-month), $300 (three-month); annual cap up to $1,300; up to 13 fills per calendar year.
• Government insurance (Medicare, Medicaid, TRICARE, VA): not eligible.
• Current card expires December 31, 2026.

LillyDirect self-pay vials.

A self-pay pathway for Zepbound single-dose vials with a valid on-label prescription, regardless of insurance status. As of February 2026:

• 2.5 mg starting dose: $299/month (down from $349)
• 5 mg: $399/month (down from $499)
• 7.5 mg, 10 mg, 12.5 mg, 15 mg: $449/month (down from $499)
• Available via LillyDirect home delivery and, since October 2025, Walmart Pharmacy retail pickup.

Trade-off: no insurance accumulator credit and no contribution toward the Part D out-of-pocket cap.

Novo Nordisk: NovoCare programs.

• Wegovy savings card. Eligible commercially-insured patients may pay as little as $25 per month, subject to a $100 per month maximum cap; restrictions apply; government beneficiaries excluded.
• Wegovy self-pay, new patient. $199/month for the first two fills of 0.25 mg and 0.5 mg through June 30, 2026; then $349/month.
• Ozempic self-pay, new patient. $199 for two monthly fills through June 30, 2026; then $349/month.
• Patient Assistance Program. Ozempic available to uninsured patients at or below 200% of the federal poverty level. Medicare Part D beneficiaries are being removed from the PAP starting January 2026, a direct consequence of the Bridge launch.

Eligibility for these cards changes frequently. Verify on the manufacturer's site (NovoCare.com or zepbound.lilly.com) before relying on a number.

Medicaid coverage.

Medicaid coverage of GLP-1s for obesity is sparse and shrinking. As of January 2026 (KFF), only 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service. Four states (California, New Hampshire, Pennsylvania, South Carolina) dropped coverage in 2025; Massachusetts and Rhode Island are reportedly considering dropping.

Roughly 80% of adult Medicaid enrollees live in states with no obesity GLP-1 pathway as of early 2026. Coverage for type 2 diabetes is far more universal, because federal law requires prescription drug coverage for FDA-approved drugs used on-label for diabetes. BALANCE is intended to expand Medicaid access via federal-state negotiation of lower prices; it is expected to begin May 2026 and run five years.

The compounded pathway closure.

Through 2023 and 2024, semaglutide and tirzepatide were on the FDA drug shortage list. Under the FD&C Act, that put 503A compounding pharmacies and 503B outsourcing facilities in a window of enforcement discretion to compound essentially-the-same drug, which fed the $200 to $400 per month compounded semaglutide market that grew up around telehealth.

That window has closed in stages:

• Tirzepatide. FDA declared the shortage resolved on December 19, 2024. 503A enforcement discretion ended February 18, 2025; 503B enforcement discretion ended March 19, 2025.
• Semaglutide. FDA declared the shortage resolved on February 21, 2025. 503A enforcement discretion ended April 22, 2025; 503B enforcement discretion ended May 22, 2025.
• Further closure. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no clinical need for outsourcing facilities to compound from bulk active ingredient.

Compounded GLP-1 used to be a cost workaround. As of spring 2025, that legal pathway has closed.

Legal supply of compounded semaglutide and tirzepatide from large compounding operations effectively ended in spring 2025. Products still sold as "compounded GLP-1" online from non-503A or non-503B sources operate in a much narrower legal zone, and FDA's warnings about sterility failures, dosing variation, salt-form discrepancies, and fake-label fraud apply with extra force once the regulatory cover is gone. Symptra does not recommend compounded GLP-1s as a cost-saving alternative.

A brief global note.

US list prices are unusually high by global standards. The UK NHS pays roughly £122/month for Mounjaro at the maintenance 15 mg dose and added tirzepatide to the GP contract effective April 1, 2026 (initial eligibility: BMI 40+ with specified comorbidities). In Canada, Ozempic and Wegovy list well below US prices. This is context for why US patients ask why drugs cost so much more here; it is not a recommendation to import medication.

Practical conversations.

What people actually do when the gap between list price and what they can pay is large, described observationally.

Five questions for your insurer.

1. Is this drug on your formulary? At what tier? For which indication?
2. Does it require prior authorization? What clinical criteria?
3. Is there step therapy? Which drugs must I try first?
4. What is my expected copay or coinsurance at my pharmacy?
5. If denied, what is the appeals process and what documentation should the prescriber submit?

Documentation that supports prior authorization.

• BMI documented at two or more visits, or BMI plus a comorbidity diagnosis for the lower threshold.
• ICD-10 codes for relevant comorbidities (E11 for T2D, I10 for hypertension, E78 for dyslipidemia, G47.33 for OSA, R73.03 for prediabetes).
• Prior weight management efforts, typically 3 to 6 months.
• For step therapy plans: prior trial-and-failure records.

Out-of-pocket realities people describe.

Online communities discuss splitting pens, holding doses, or skipping weeks to stretch supply when refills get expensive. Pattern worth naming, not endorsing: multi-dose pens are not designed for accurate volume splitting, and under-dosing risks losing the benefit you are paying for. If cost is forcing a workaround, the appropriate move is a conversation with your prescriber about a planned step-down to a lowest effective dose, or, if stopping is on the table, a prescriber-led plan that anticipates weight regain rather than is surprised by it.

Verifying any pharmacy you are considering.

• Check state board of pharmacy licensing for the dispensing pharmacy.
• Look for VIPPS accreditation (NABP).
• For any compounded product a prescriber has written, ask whether the dispensing facility is 503A (state-licensed) or 503B (FDA-registered); ask for certificates of analysis.
• Red flags: no prescription required, prices well below the cheapest manufacturer self-pay, no pharmacist available, refusal to share lot numbers.

For daily injection liraglutide products and any weekly pen used in site rotation across abdomen, thigh, and upper arm, technique conversations matter alongside cost.

Reading a savings card's fine print.

• Eligibility: most cards require commercial insurance; government beneficiaries excluded.
• Per-fill and per-year savings caps.
• Calendar-year fill limits (Lilly's is up to 13 fills per year).
• Expiration date (Lilly's currently 12/31/2026).
• Whether the card stacks with a manufacturer copay assistance program.

What this article is not.

Not financial advice, and not a recommendation to switch medications, switch indications, or pursue a particular pharmacy. The cost landscape moves quarterly; verify any specific number with your insurer, your prescriber, the manufacturer page, or the CMS GLP-1 Bridge page before acting. The right medication at the right dose, taken consistently, is what determines whether the spending produces a clinical outcome. Cost belongs in that conversation, but it does not replace it.

This article is for educational purposes only and is not medical, legal, or financial advice. Figures reflect May 2026; confirm pricing and Medicare eligibility at official CMS and manufacturer sites before deciding. Always consult your prescriber, pharmacist, and plan's benefits administrator about your specific situation. See our editorial process for how we source and update content. By the Symptra Editorial Team.